#LSIUSA24 is in the books, and it was such a fabulous conference. Caeli Vascular is so appreciative of the opportunity to engage in sessions, participate in valuable meetings, and for our CEO Tom Douthitt to present the benefits and opportunity that Caeli’s platform technology will bring to the treatment of DVT along the entire continuum from acute through late stage chronic disease. The response to the Caeli story has been tremendous, and we look forward to the encore #LSIUSA24 sessions in 2025.
Caeli Vascular, Inc.
Medical Equipment Manufacturing
ST. LOUIS, MO 139 followers
Transformative treatment for the full spectrum of venous obstructive disease.
About us
Caeli Vascular has developed a proprietary catheter-based modular multi-modal technology platform for treating venous obstructive disease along the entire disease continuum from early acute through chronic stages. Chronic disease, in particular, remains a significant unmet need afflicting over 250,000 patients in the U.S. annually and is a significant financial burden on the healthcare system. Caeli’s system provides infusion, clot fragmentation, and aspiration all within a confined treatment zone that minimizes embolization, bleeding, and blood loss during aspiration. With its multimodal closed system design, the Caeli Vascular SPECTRUM system improves outcomes, enhances safety margins, and reduces costs.
- Website
-
http://www.caelivascular.com
External link for Caeli Vascular, Inc.
- Industry
- Medical Equipment Manufacturing
- Company size
- 2-10 employees
- Headquarters
- ST. LOUIS, MO
- Type
- Privately Held
- Founded
- 2019
- Specialties
- vascular, endovascular, medical devices, and DVT
Locations
-
Primary
Get directions
4340 Duncan Ave
Biogenerator Suite 221
ST. LOUIS, MO 63110, US
-
Get directions
BioGenerator
4340 Duncan Avenue
St. Louis, MO 63110, US
Employees at Caeli Vascular, Inc.
-
Tom Douthitt
CEO @ Caeli Vascular Inc.
-
John H.
Chief Executive Officer at Caeli Vascular, Inc.
-
Eric Leuthardt
Neurosurgeon-Scientist, Innovator, Entrepreneur, Investment Expert
-
Richard Van Bibber, PhD
Experienced medtech executive with clinical, regulatory, quality, professional education and technology assessment background
Updates
-
We are excited to announce that our CEO, Tom Douthitt, has been selected to present at the #lsiusa24 Emerging MedTech Summit 2024. Please join us on Thursday, March 21st, at 2:20pm PT.
-